Effects of 5-Aminolevulinic Acid on Iron Deficiency Anemia

Hiroshima University135 enrolled

Overview

This study is designed to evaluate efficacy and dose-dependency of 5-aminolevulinic acid in subjects with iron deficiency anemia.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

DOUBLE

Enrollment

135

Conditions

Iron Deficiency Anemia

Interventions

PlaceboDIETARY_SUPPLEMENT

Placebo; once/day; for 12 weeks

Iron aloneDIETARY_SUPPLEMENT

Iron (3 mg); once/day; for 12 weeks

Low-dose 5-aminolevulinic acid with ironDIETARY_SUPPLEMENT

5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 49 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Premenopausal women with hemoglobin ≥ 9.0 g/dl and ≤ 12.0 g/dl * Willing not to donate blood during the study * Informed consent signed Exclusion Criteria: * History of porphyria, hemochromatosis, or viral hepatitis * Anemia other than iron deficiency * BMI ≤ 18 kg/m2 or ≥ 30 kg/m2 * Pregnant or nursing a child * Participation in any clinical trial within 90 days of the commencement of the trial * Renal or hepatic dysfunction * Heart disease * Subjects who are taking medicines or functional food that may affect hemoglobin level

Locations (1)

Hiroshima University

Hiroshima, Japan